ライフサイエンスコーパス: DPP

1 DPP appears to be synthesized as a part of a larger comp

2 DPP is found to disturb cellular metabolism including in

3 DPP IV is responsible of the degradation of the incretin

4 DPP lifestyle modification programs achieved clinically

5 DPP nontreponemal line sensitivity was 94.2% (95% CI, 91

6 DPP test outcome (pair of test lines) was concordant wit

7 DPP test use would result in identification of >93% of a

8 DPP was similar in the 2 groups, and proportions of pati

9 DPP-4 inhibition reduced glycemia and enhanced insulin l

10 DPP-4 inhibitors were associated with lower risks for al

11 DPP-IV activity in cHSA was compared with other sources

12 DPP-IV inhibitory peptide sequences identified within ca

13 single policy studied (approximately 230,000 DPPs by 2030) while also significantly reducing disparit

14 ersible inhibitor of dipeptidyl peptidase 1 (DPP-1), an enzyme responsible for the activation of neut

15 ligible individuals, by approximately 8% (10 DPPs per 100,000 population).

16 approximately 31,000 (95% UI 26,800-35,300) DPPs for a 10% SSB tax.

17 inedione (SMD, 0.16 [95% CI, 0.00 to 0.31]), DPP-4 inhibitor (SMD, 0.33 [95% CI, 0.13 to 0.52]), and

18 Sequence alignment of 39 DPP-IV inhibitory peptides having IC50's<200 muM reveale

19 erapeutic effects of dipeptidyl peptidase 4 (DPP-4) inhibition (vildagliptin) by using the GLP-1 rece

20 potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profi

21 sed drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) an

22 rated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of p

23 or (GLP-1) agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, peroxisome proliferator-activated rec

24 ts and inhibitors of dipeptidyl peptidase-4 (DPP-4) have shown pleiotropic effects on bone metabolism

25 o had baseline serum dipeptidyl peptidase-4 (DPP-4) higher than the population baseline median, we no

26 4 patients with T2D, dipeptidyl peptidase-4 (DPP-4) inhibition and its glucose-lowering actions were

27 as as effective as a dipeptidyl peptidase-4 (DPP-4) inhibitor at reducing peak glucose levels in an a

28 Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibitor that inhibits the degradation of glucag

29 Dipeptidyl peptidase-4 (DPP-4) inhibitors have pleotropic anti-inflammatory and

30 In this regard, dipeptidyl peptidase-4 (DPP-4) inhibitors have recently been reported to attenua

31 glucose lowering by dipeptidyl peptidase-4 (DPP-4) inhibitors is unclear.

32 Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent degradation of incretin hormon

33 udies concluded that dipeptidyl peptidase-4 (DPP-4) inhibitors provide glycemic control but also rais

34 GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors represent 2 distinct classes of incret

35 ones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (S

36 hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety

37 mparator drug class, dipeptidyl peptidase-4 (DPP-4) inhibitors, in patients with type 2 diabetes.

38 ion by inhibition of dipeptidyl peptidase-4 (DPP-4) promotes glycemic reduction for the treatment of

39 are both cleaved by dipeptidyl peptidase-4 (DPP-4); hence, inhibition of DPP-4 activity enables yet

40 opeptidases, such as dipeptidyl peptidase-4 (DPP-4, CD26), are potent therapeutic targets for pharmac

41 thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like peptide 1 [GLP-1] recep

42 approximately 25,800 (95% UI 24,300-28,500) DPPs for a 1-y MMC, or the approximately 31,000 (95% UI

43 approximately 35,100 (95% UI 31,700-37,500) DPPs potentially attributable to a 30% F&V subsidy targe

44 The model takes 68 DPP-IV inhibitory peptides (having an IC50 value <2000 m

45 reducing disparities, by approximately 6% (7 DPPs per 100,000 population).

46 al insulin (TZDs: HR 0.55, 95% CI 0.38-0.81; DPP-4is: HR 0.56, 95% CI 0.39-0.82).

47 half the effect seen with the addition of a DPP-4 inhibitor, and equated to a dose difference of 550

48 The power conversion efficiency (PCE) of a DPP-based polymer solar cell is significantly improved b

49 thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control

50 effects on cardiovascular outcomes of adding DPP-4 inhibitors versus sulfonylureas to metformin thera

51 on at 7.0 displayed higher ORAC activity and DPP-IV inhibitory properties compared to the associated

52 advances that reveal how GLP-1R agonists and DPP-4 inhibitors affect the normal and diabetic heart an

53 es demonstrate that both GLP-1R agonists and DPP-4 inhibitors exhibit cardioprotective actions in ani

54 ardiovascular actions of GLP-1R agonists and DPP-4 inhibitors, with a focus on the translation of mec

55 for unequal amounts of intracellular DSP and DPP.

56 od was collected for analysis of glucose and DPP-4 levels.

57 nts, respectively, and the basal insulin and DPP-4i groups contained 6,051 and 11,900 patients, respe

58 ox models with exposure to sulfonylureas and DPP-4 inhibitors included as time-varying covariates wer

59 TZDs and DPP-4is were both associated with similar risks of MACEs

60 Val to the secondary binding sites of XO and DPP-IV is required.

61 ates of in-hospital heart failure in another DPP-4 inhibitor trial have been reported.

62 aintenance of target gene domains as well as DPP's role in growth control.

63 nefits over currently commercially available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified

64 is more than twice that of the sulfur-based DPP derivative and represents the highest value for p-ty

65 mic behaviors of diketopyrrolopyrrole-based (DPP-based) semiconducting polymers.

66 GLP-1 signaling is unclear, however, because DPP-4 cleaves other molecules as well.

67 interaction between expansion and TGF-beta (DPP) signaling was observed.

68 e transforming growth factor-beta (TGF-beta, DPP) signaling pathway.

69 dominant negative plasmid of CaMKII, blocked DPP-mediated Smad1 phosphorylation.

70 diabetes incidence declined 0.3 per 1,000 by DPP, 0.2 by DPP-YMCA, and 0.4 by HELP-PD over the 15-yea

71 idence declined 0.3 per 1,000 by DPP, 0.2 by DPP-YMCA, and 0.4 by HELP-PD over the 15-year period.

72 The cardiovascular mechanisms engaged by DPP-4 inhibition are more complex, encompassing increase

73 -36), a cardioactive metabolite generated by DPP-4-mediated cleavage.

74 The majority of angioedema induced by DPP IV inhibitors occurs during concomitant treatment wi

75 an be committed to the osteogenic lineage by DPP.

76 aQuick Advance Rapid HIV-1/2 and the Chembio DPP HIV-1/2) from May to September 2009 in two CT sites

77 The Chembio DPP OF test showed 519 (31.0%) reactive samples and 1,15

78 The Chembio DPP Zika ICA and InBios ZIKV 2.0 MAC-ELISA showed >95% s

79 NT-confirmed ZIKV samples, while the Chembio DPP Zika ICA was nonreactive in three (20%) and the InBi

80 Among these are the Chembio DPP Zika IgM system (DPP Zika ICA; Chembio, Medford, NY)

81 d that the binding energies of Zn-DPP and Co-DPP are significantly higher than those of Ni-DPP and Cu

82 , blends of the narrow optical gap copolymer DPP-DTT with PC70BM show two distinct spectrally flat re

83 ificantly higher than those of Ni-DPP and Cu-DPP.

84 uch as the TGF-beta homolog Decapentaplegic (DPP).

85 In this paper, we show that Decapentaplegic (DPP) and JNK form a coherent FFL that controls the speci

86 cessary for TF upconversion and demonstrates DPPs as a new class of annihilator molecules.

87 Relatively potent alpha-lactalbumin-derived DPP-IV inhibitory peptides (LAHKPL and ILDKEGIDY) were d

88 The most potent camel milk protein-derived DPP-IV inhibitory peptides, LPVP and MPVQA, had DPP-IV h

89 ith zwitterion-substituted dibromothiophene, DPP, and NDI monomers by A2 + B2 Suzuki polymerization.

90 harge generation for a total of 16 different DPP polymers, we confirm that the minimal driving force,

91 monly reported materials, but also difuranyl-DPP, diselenophenyl-DPP and dithienothienyl-DPP-containi

92 yl]tellurophene with a diketopyrrolopyrrole (DPP) monomer.

93 methene (BODIPY) dyes, diketopyrrolopyrrole (DPP) dyes, and electron donor fragments based on triaryl

94 - and selenyl- flanked diketopyrrolopyrrole (DPP) derivatives as pai-bridges.

95 ects are found in many diketopyrrolopyrrole (DPP)-based copolymers reported in the literature.

96 ur different 2-pyridyl diketopyrrolopyrrole (DPP) polymer-fullerene solar cells.

97 f selenium-substituted diketopyrrolopyrrole (DPP) derivatives.

98 ontaining thiophene-, diketopyrrolopyrrole- (DPP), and naphthalene diimide (NDI) backbones, were synt

99 the singlet energy of diketopyrrolopyrroles (DPPs) can be altered by modifying the pendant aryl subst

100 t transistor applications including diphenyl-DPP and dithienyl-DPP-based polymers as the most commonl

101 In our effort to discover DPP-4 inhibitors with added benefits over currently comm

102 ials, but also difuranyl-DPP, diselenophenyl-DPP and dithienothienyl-DPP-containing polymers.

103 -DPP, diselenophenyl-DPP and dithienothienyl-DPP-containing polymers.

104 cations including diphenyl-DPP and dithienyl-DPP-based polymers as the most commonly reported materia

105 i.e., the Diabetes Prevention Program (DPP), DPP-YMCA, and the Healthy Living Partnerships to Prevent

106 posed of 3 parts: dentin sialoprotein (DSP), DPP, and dentin glycoprotein (DGP).

107 However, ectopic DPP cannot rescue the anterior fate formation, suggestin

108 for the degradation of the non-electroactive DPP into phenol, which is directly measured by differenc

109 hydrogen microbubbles and hydroxyl ions for DPP degradation.

110 The classical mechanism for DPP-4 inhibitors is that they inhibit DPP-4 activity in

111 humans have found additional mechanisms for DPP-4 inhibitors that may contribute to their glucose-lo

112 17.9 10(-6) muM(-1)g(-1)), respectively for DPP-IV inhibitory peptides.

113 The results were similar for DPP-4 inhibitors and GLP-1 analogues.

114 Furthermore, DPP-4 inhibition rescued WD-induced decreases in hepatic

115 Es) of about 5%, while the narrow-energy-gap DPP- and NDI-based CPZs performed exceptionally well, gi

116 investigate a parametric family of Gaussian DPPs with a clearly interpretable effect of parametric m

117 ical mechanisms include 1) inhibition of gut DPP-4 activity, which prevents inactivation of newly rel

118 -IV inhibitory peptides, LPVP and MPVQA, had DPP-IV half maximal inhibitory concentrations (IC50) of

119 CN-derived peptides, VPV, YPI and VPF having DPP-IV IC(50) values of 6.6 +/- 0.5, 35.0 +/- 2.0 and 55

120 The highest DPP-IV inhibitory activity was found with the amino acid

121 also highlight outstanding questions of how DPP coordinates patterning and growth during development

122 a-glucosidase, and dipeptidyl peptidase III (DPP III) enzyme activities.

123 om studies in the United States implementing DPP lifestyle modification programs (focused on modest [

124 tor changes observed in studies implementing DPP interventions in nonresearch settings in the United

125 ss (agreement: 85.0% in Look AHEAD; 87.4% in DPP).

126 ss (agreement: 91.6% in Look AHEAD; 90.5% in DPP).Although all of the criteria discriminated on the b

127 e serology (T1 and T2) to monitor changes in DPP optical density (using an automatic reader) at 3 and

128 : 6.6-11.9 kg in Look AHEAD; 11.5-14.6 kg in DPP; P < 0.0001).

129 sm for DPP-4 inhibitors is that they inhibit DPP-4 activity in peripheral plasma, which prevents the

130 G-CSF), a dipeptidyl peptidase IV inhibitor (DPP-4i), and a proton pump inhibitor (PPI).

131 (TZDs) or dipeptidyl peptidase-4 inhibitors (DPP-4is) as a third antidiabetic agent in patients with

132 rtal GLP-1 receptors; 2) inhibition of islet DPP-4 activity, which prevents inactivation of locally p

133 oline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed in mammalians, re

134 ed by the action of dipeptidyl peptidase IV (DPP-4) which limits their use as therapeutic agents.

135 ne oxidase (XO) and dipeptidyl peptidase IV (DPP-IV) inhibition by amino acids and dipeptides was stu

136 ng enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory activities, with inhibition of ACE be

137 ng enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory and oxygen radical absorbance capacit

138 Nine novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (FLQY, FQLGASPY, ILDKEGIDY,

139 mise the release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides during hydrolysis of bovine

140 act as a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.

141 lk proteins contain dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.

142 of pH regulation on dipeptidyl peptidase IV (DPP-IV) properties.

143 to act as preferred dipeptidyl peptidase IV (DPP-IV) substrates.

144 tivities, including dipeptidyl peptidase-IV (DPP-IV) and angiotensin converting enzyme I (ACE) inhibi

145 apid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

146 apid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

147 ecific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed in mammalians, releases X

148 roperties of M(II)-5,15-diphenylporphyrin (M-DPP) single-molecule junctions (M=Co, Ni, Cu, or Zn diva

149 ht was reduced or maintained with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 in

150 particular through a pivotal monosubstituted DPP building block with a reactive bromo substituent.

151 tering the highly conserved catalytic motif (DPP(Y/F)) as well as the AdoMet-binding motif (FXGXG) by

152 Using this new DPP platform, the output wavelength from upconversion ca

153 ounterparts, ranging from 2.10(-2) G0 for Ni-DPP up to 8.10(-2) G0 for Zn-DPP.

154 PP are significantly higher than those of Ni-DPP and Cu-DPP.

155 Camel milk proteins contain novel DPP-IV inhibitory peptides which may play a role in the

156 Three novel DPP-IV inhibitory peptides, Ile-Leu-Ala-Pro, Leu-Leu-Ala

157 This progress report summarizes the numerous DPP-containing polymers recently developed for field-eff

158 rculation and enhanced tumor accumulation of DPP due to its unique molecular structure.

159 ccessfully applied to the direct analysis of DPP in selected food and biological samples, without any

160 tagliptin reduced the serum concentration of DPP-4.

161 blood glucose is impaired; 2) the effect of DPP-4 inhibition on glycemia is likely to depend on adeq

162 blockade, whereas the inhibitory effects of DPP-4 inhibition on glucagon and GE were abolished.

163 antagonist, the glucose-lowering effects of DPP-4 inhibition were reduced by approximately 50%.

164 significantly to the therapeutic effects of DPP-4 inhibition.

165 es GLP mediating the antidiabetic effects of DPP-4 inhibition.

166 pic effects may contribute to the effects of DPP-4 inhibition.

167 Examinations of DPP- and gingipain gene-disrupted mutants indicated that

168 Several families of DPP IV inhibitors have been synthesized and evaluated.

169 The function of DPP has been studied at multiple levels: ranging from th

170 We propose that the main function of DPP pathway during Drosophila DC is to ensure robust mor

171 yl peptidase-4 (DPP-4); hence, inhibition of DPP-4 activity enables yet another pathway for potentiat

172 ivation of GLP-1R signaling or inhibition of DPP-4 activity produces a broad range of overlapping and

173 LP-1 system by pharmacological inhibition of DPP-4 caused hyperinsulinemia, suppression of glucagon r

174 hibitor of XO and a competitive inhibitor of DPP-IV.

175 ovascular drug classes, namely inhibitors of DPP IV or neprilysin, have been developed.

176 Significant levels of DPP-IV activity were present in cHSA.

177 d discusses these nonclassical mechanisms of DPP-4 inhibition.

178 Different modes of DPP-IV inhibition were observed depending on the test co

179 of 10,089 propensity score-matched pairs of DPP-4 inhibitor users and sulfonylurea users were examin

180 c therapy (PDT) treatment in the presence of DPP, resulting in attenuated cancer cell growth and even

181 receipt of SGLT-2 inhibitors with receipt of DPP-4 inhibitors, which were pooled by using random-effe

182 l propensity scores to 208 757 recipients of DPP-4 inhibitors.

183 ments during the translational regulation of DPP.

184 f food proteins for the enzymatic release of DPP-IV inhibitory peptides.

185 heat were identified as potential sources of DPP-IV inhibitory peptides.

186 ogical functions and potential substrates of DPP IV enzymes are reviewed and the characteristics of t

187 the DSPP gene that directs the synthesis of DPP.

188 nhibition of ACE being stronger than that of DPP-IV.

189 Compared with use of DPP-4 inhibitors, use of liraglutide was associated with

190 use of liraglutide, as compared with use of DPP-4 inhibitors, was associated with significantly redu

191 per 1000 person-years) and in 1141 users of DPP-4 inhibitors (15.4 per 1000 person-years; hazard rat

192 s of liraglutide and 23 402 matched users of DPP-4 inhibitors; patients were followed up for a mean o

193 trials, along with the potential utility of DPP-4 and periostin as biomarkers of interleukin-13 path

194 nt publications that both enrich our view of DPP signaling but also highlight outstanding questions o

195 Our results indicate that the wiring of DPP signaling buffers against environmental challenges a

196 atly diversify the number of applications of DPPs in upconversion technologies.

197 erature and time had a significant effect on DPP-IV inhibitory properties (p<0.05) in contrast with E

198 Rates of diastolic OPP (DPP)</=50, </=40, </=30 mmHg in the 2 groups were calcul

199 rt included incident users of liraglutide or DPP-4 inhibitors, who were also using metformin at basel

200 The dipeptidyl peptidase (DPP) 4 family includes four enzymes, DPP4, DPP8, DPP9 an

201 Dipeptidyl peptidase (DPP)-4 inhibition is a glucose-lowering treatment for ty

202 and thermodynamics of dipeptidyl peptidase (DPP)-4 inhibitors (gliptins) were investigated using sur

203 Dipeptidyl peptidase (DPP)-IV inhibitory peptides were purified and identified

204 Dipeptidyl peptidases (DPPs) are proteolytic enzymes that are ideal therapeutic

205 y against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PRE

206 processes mediated by dipeptidyl-peptidases (DPPs) should be beneficial for the organism.

207 ic structure calculations reveal that phenyl-DPP bridge localizes alpha- and beta-spin densities on d

208 ne-rich protein called dentin phosphophoryn (DPP).

209 lycoprotein (DGP) and dentin phosphoprotein (DPP).

210 direct determination of diphenyl phthalate (DPP) in food and biological samples is presented.

211 point-of-care assay-the Dual Path Platform (DPP) syphilis assay, which is based on simultaneous dete

212 pyropheophorbide a (Ppa)-conjugated polymer (DPP) is reported, and a linear Ppa-conjugated polymer (L

213 -158,500) CVD deaths prevented or postponed (DPPs) by 2030 in the US.

214 fluorinated biomolecules including a potent DPP-II inhibitor and acyclonucleoside analogues as poten

215 After IPI, VPV is the second most potent DPP-IV inhibitory peptide identified to date, which supp

216 his method to screening drugs with potential DPP-4 inhibitory activity.

217 Determinantal point processes (DPPs) have recently become popular tools for modeling th

218 By using dynamic proteome profiling (DPP), we investigated the contribution of both synthesis

219 n CRFs in 2,658 Diabetes Prevention Program (DPP) participants.

220 The Diabetes Prevention Program (DPP) study showed that weight loss in high-risk adults l

221 icipants of the Diabetes Prevention Program (DPP) with genetic consent.

222 rofiling in the Diabetes Prevention Program (DPP), a completed trial that randomized high-risk indivi

223 Within the Diabetes Prevention Program (DPP), a trial for the prevention of type 2 diabetes amon

224 mpared with the Diabetes Prevention Program (DPP), decreased in the placebo (-42%) and metformin (-25

225 rams, i.e., the Diabetes Prevention Program (DPP), DPP-YMCA, and the Healthy Living Partnerships to P

226 d data from the Diabetes Prevention Program (DPP), we examined power in conventional and genotype-bas

227 amples from the Diabetes Prevention Program (DPP).

228 ; n = 1791) and Diabetes Prevention Program (DPP; n = 613) participants with >/=3% initial weight los

229 ype 2 diabetes (Diabetes Prevention Program [DPP]; N = 917/907 intervention/comparison) or with type

230 d here matches with previous data on related DPP-based polymers.

231 re settings (median, $424) than for the U.S. DPP (Diabetes Prevention Program) trial and the DPP Outc

232 Aligned films of a semiconducting DPP-based copolymer exhibit highly anisotropic charge tr

233 Presently, several DPP IV inhibitors, the "gliptins", are approved for type

234 simulated gastrointestinal digestion (SGID, DPP-IV IC50=0.60+/-0.06vs.

235 Thus, a significant DPP-4-sensitive glucose-lowering mechanism contributes t

236 ncer drug mitoxantrone possesses significant DPP-4 inhibitory activity both in vitro and in vivo.

237 urrently implemented RPR test to the simpler DPP assay could ease the implementation of yaws eradicat

238 f exenatide (GLP-1 agonist) and sitagliptin (DPP-4 inhibitor) during periodontitis induction by ligat

239 Compared with sulfonylureas, DPP-4 inhibitors were associated with lower risks for al

240 g these are the Chembio DPP Zika IgM system (DPP Zika ICA; Chembio, Medford, NY), a rapid immunochrom

241 ioavailability of functional foods targeting DPP-IV inhibition with potential blood glucose regulator

242 Among 1005 serum samples tested, DPP treponemal line sensitivity was 89.8% (95% confidenc

243 unction approaches, we also demonstrate that DPP is essential for the formation of well-defined tooth

244 Further, we provide evidence that DPP is transported to the extracellular matrix (ECM) thr

245 nd metformin-based combinations, except that DPP-4 inhibitors had smaller effects.

246 In this report, we show that DPP binds to annexin 2 and 6 present in a rat ureteric b

247 These findings suggest that DPP is capable of triggering commitment of pluripotent s

248 These studies suggest that DPP-4 inhibition ameliorates hepatic steatosis and insul

249 This suggests that DPP-4 inhibition has the potential to reduce cardiovascu

250 The DPP (Diabetes Prevention Program) was a randomized contr

251 The DPP assay is accurate for identification of antibodies t

252 The DPP T1 (treponemal) assay had a sensitivity of 88.4% (95

253 The DPP T2 (non-treponemal) assay had a sensitivity of 87.9%

254 The DPP-4 inhibitor prevented WD-induced hepatic steatosis a

255 The DPP-IV half maximal inhibitory concentration (IC50) of H

256 festyle intervention over 4 years across the DPP and Look AHEAD.

257 (Diabetes Prevention Program) trial and the DPP Outcomes Study ($5881).

258 senatide in Acute Coronary Syndrom]) and the DPP-4 inhibitors saxagliptin (SAVOR-TIMI 53 trial [Saxag

259 hat through repression by Brinker (Brk), the DPP branch of the FFL filters unwanted JNK activity.

260 ose Western diet (WD) or a WD containing the DPP-4 inhibitor, MK0626, for 16 weeks.

261 nor impact on the device performance for the DPP- and NDI-CPZs, a finding attributed to their electro

262 This approach was examined in the DPP (Diabetes Prevention Program) and the DPPOS (Diabete

263 mates and allele frequencies reported in the DPP for the rs8065082 SLC47A1 variant, a metformin trans

264 hange in ISI over 1 year of follow-up in the DPP intervention (metformin and lifestyle) and control (

265 omparisons in Look AHEAD and 13 of 28 in the DPP were in high agreement.

266 Ninety proteins were included in the DPP, with 28 proteins exhibiting significant responses t

267 years, 1.76), compared with 57 events in the DPP-4 inhibitor group (IR, 1.77) (HR, 0.98 [95% CI, 0.68

268 metformin groups compared with those in the DPP.

269 lated the sensitivity and specificity of the DPP assay for detection of antibodies to treponemal (T1)

270 are reviewed and the characteristics of the DPP IV inhibitors are discussed in view of type 2 diabet

271 The metal ion in the center of the DPP skeletons is strongly coordinated with the nitrogens

272 re of 1:8 or greater, the sensitivity of the DPP T2 assay was 94.1% (95% CI 89.9-96.9).

273 EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to placebo on major adverse c

274 ews the most recent CV outcome trials of the DPP-4 inhibitors (SAVOR-TIMI 53, EXAMINE, and TECOS) as

275 ant improvement in the stretchability of the DPP-based polymers without adversely affecting their mob

276 ly factor having a significant effect on the DPP-IV IC(50) value (p < 0.05).

277 goal was to ascertain at what timepoint the DPP assay line reverted to negative after treatment.

278 the thiophene donor of one molecule with the DPP core acceptor in another molecule as observed in the

279 us (HIV) infection during treatment with the DPP-4 inhibitor sitagliptin.

280 ciated with weight loss or regain within the DPP and Look AHEAD trials, directly or via interactions

281 Their DPP-IV half maximal inhibitory concentrations (IC(50)) r

282 h-throughput live imaging revealed that this DPP/Brk branch is dispensable for DC under normal condit

283 iptin increased intact GLP-1 and GIP through DPP-4 inhibition but reduced total GLP-1 and GIP (feedba

284 Binding of gliptins to DPP-4 is a rapid electrostatically driven process.

285 (5.6 +/- 1.7 mmol/mol) lower A1C response to DPP-4 inhibitor treatment in G-allele carriers, but ther

286 sH were prodrug- while WPH and LFH were true DPP-IV inhibitors.

287 activity was found with the amino acid Tyr (DPP-IV IC50=75.15+/-0.84muM).

288 e initiating use of SGLT-2 inhibitors versus DPP-4 inhibitors (cohort 1) or GLP-1 agonists (cohort 2)

289 PLR, IIAEKTKIPAVF, IDALNENK, and VLVLDTDYK), DPP-IV-inhibitory peptides (LKALPMH, LKPTPEGDLEIL, LKGYG

290 G) content was significantly attenuated with DPP-4 inhibitor treatment.

291 Compared with DPP-4 inhibitors, SGLT-2 inhibitors were associated with

292 The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.

293 gastrointestinal enzymes were incubated with DPP-IV at 37 degrees C for 18 or 24h.

294 akdown was evident following incubation with DPP-IV.

295 Several peptides with DPP-IV inhibitory features or known activity were identi

296 t 2 Australian laboratories were tested with DPP Screen and Confirm Assay.

297 lin excursion after an OGTT with and without DPP-4 inhibition.

298 0(-2) G0 for Ni-DPP up to 8.10(-2) G0 for Zn-DPP.

299 with its higher conductance, we identify Zn-DPP as the favoured candidate for high-conductance CPP s

300 We find that the binding energies of Zn-DPP and Co-DPP are significantly higher than those of Ni